Friday 29 September 2023 - 02:50
In Business 43 Years - Since 1980
NOTE: our usual phone and fax lines are down, due to a dispute between our landlord and Verizon.
In the meantime, please use this mobile phone number: 978-715-9327 and this fax number:
The 25% Discount for Shopping Cart Purchases is now PERMANENT !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
Search:
P-5115 Pemafibrate, Free Acid, >99%
Synonyms : [K-877] [R-K-13675]
Related Terms : [Parmodia]
- Size
- US $
- €
- £
- ¥
- 1 mg
- 43
- 40
- 35
- 6,400
- In stock
- 5 mg
- 64
- 60
- 52
- 9,600
- In stock
- 10 mg
- 98
- 93
- 80
- 14,600
- In stock
- 25 mg
- 199
- 188
- 163
- 29,700
- In stock
- 50 mg
- 340
- 322
- 278
- 50,800
- In stock
- 100 mg
- 520
- 493
- 426
- 77,700
- In stock
- 200 mg
- 874
- 829
- 716
- 130,500
- In stock
- 500 mg
- 1,790
- 1,698
- 1,467
- 267,300
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 32 Other Countries
- M.W. 490.55
- C28H30N2O6
- [848259-27-8]
Solubility: DMSO.
- Pemafibrate, also known as K-877, is a selective peroxisome proliferator-activated receptor [alpha] (PPAR[alpha]) modulator and a next-generation PPAR[alpha] agonist. It activated PPAR[alpha], PPAR[gamma], and PPAR[delta] with EC50 values of 1 nM, 2.3 uM, and 1 uM, respectivey. Fruchart J.C. "Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists." Cardiovasc Diabetol. 12: 82 (2013).
- When compared to placebo and fenofibrate, pemafibrate improved triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and other lipid parameters without increasing adverse events or adverse drug reactions in dyslipidaemic patients with high TG and low HDL-C. Ishibashi S., et al. "Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial." Atherosclerosis 249: 36-43 (2016).
- Pemafibrate suppressed diet-induced obesity; decreased plasma glucose, insulin and TG levels; increased plasma fibroblast growth factor 21 in mice; and improved their obesity-related metabolic abnormalities. Araki M., et al. "The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice." Int. J. Mol. Sci. 19(7): 2148 (2018).
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
